7 results about "Ocular angiogenesis" patented technology

To provide a pharmaceutical composition for treating or preventing non-proliferative diabetic retinopathy.SOLUTION: A pharmaceutical composition containing VEGF antagonist to be used in a method for bringing about at least 2 steps of improvement in a diabetic retinopathy seriousness scale (DRSS) in a patient who has non-proliferative diabetic retinopathy and needs the composition, where the patient is not suffered from diabetic macular edema including a central part. The method includes administering approximately 2 mg of VEGF antagonist being a VEGF receptor-based chimeric molecule containing: VEGFR1 component including a specific amino acid sequence; VEGFR2 component including a specific amino acid sequence; and multimerized component including a specific amino acid sequence, for 5 times of monthly dosage and subsequent once or more of secondary dosage by every 8 weeks to an eye of the patient by intravitreal injection. The VEGF antagonist is preferably aflibercept.SELECTED DRAWING: Figure 1

Provided is an antiangiogenic agent in the form of a vehicle, e.g., a nanoparticle associated (directly or indirectly) with at least one ocular angiogenesis growth factor aptamer, wherein said association labile to interaction between the aptamer and an ocular angiogenesis growth factor.

The invention discloses eye drops for treating vascular hyperplasia of eyes and a preparation method of the eye drops, and belongs to the technical field of biological pharmacy. The eye drops comprise a recombinant human angiostatin protein, an endostatin protein and a pharmaceutically acceptable carrier, wherein the recombinant human angiostatin protein and the endostatin protein are used for preparing the eye drops. Experiments show that the eye drops show remarkable vascular inhibition activity in a chick embryo chorioallantoic membrane model and a diabetic rat retina hyperplasia model, and the two proteins are combined for use to achieve a synergistic effect; the invention provides a safe and effective new way for local treatment of ocular vascular hyperplasia diseases.

Methods for treating diseases and disorders treatable by AMPK activation with cefin-1 and related compounds, such as metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, muscle loss, neuromuscular disorders, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular disease, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, eye diseases or disorders, ocular angiogenesis, β-hemochromocytic disorder, cancer, fibrosis, cancer cachexia, and mitochondrial diseases.

The invention relates to nanoparticles, nano eye drops as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a nanoparticle. The nanoparticle is composed of a tyrosine kinase inhibitor and a carrier protein, the mass ratio of the tyrosine kinase inhibitor to the carrier protein is (2-4): 1. The tyrosine kinase inhibitor-loaded nanoparticles are prepared and creatively combined with the photosensitizer-loaded lipid vesicles to obtain the synergistic photodynamic-VEGF inhibition difunctional photoresponsive nano eye drops which are uniform in particle size, simple and feasible in preparation method and good in stability; the photosensitizer and tyrosine kinase inhibitor co-delivery hydrogel prepared by the method realizes efficient co-delivery of the photosensitizer and the tyrosine kinase inhibitor, has a laser response release behavior, can be detained in eye tissues for a long time, not only greatly improves the bioavailability of hydrophobic drugs, but also realizes the final curative effect of resisting ocular angiogenesis, and has potential clinical application value.

A carbon nanoparticle, which is produced by the step of subjecting sodium alginate and a diamine to a pyrolysis treatment at a temperature ranging from 160° C. to 200° C. The diamine is a C4-C10 linear aliphatic diamine. A method for alleviating ocular angiogenesis using the carbon nanoparticle and a method for producing the carbon nanoparticle are also provided.

The present application relates to a kind of nanoparticles, nano drop eye drops and its preparation method and application, belong to medical technology field.The present application provides a kind of nanoparticle, the nanoparticle is composed of tyrosine kinase inhibitor and carrier protein;The mass ratio of tyrosine kinase inhibitor and carrier protein is 2~4:1.The present application prepares a kind of nanoparticle loaded tyrosine kinase inhibitor, creatively combines it with light-sensitive agent loaded lipid vesicle, obtains a kind of synergistic photodynamic-VEGF inhibits bifunctional light-responsive nano drop eye drops, its particle size is uniform, preparation method is simple and easy to operate, and stability is good, realizes the efficient co-delivery of light-sensitive agent, tyrosine kinase inhibitor, with laser response release behavior, and can be long time in eye tissue Retention, not only greatly improve the bioavailability of hydrophobic drug, and realize the final curative effect of anti-ocular angiogenesis, with potential clinical application value.